On the origins of drug polypharmacology

被引:111
作者
Jalencas, Xavier
Mestres, Jordi [1 ]
机构
[1] IMIM Hosp Mar Res Inst, Res Programme Biomed Informat GRIB, Chemogen Lab, Barcelona 08003, Catalonia, Spain
关键词
PROTEIN-COUPLED RECEPTORS; STRUCTURE-BASED DISCOVERY; LIGAND-BASED APPROACH; LIBRARY DESIGN; BINDING-SITES; TARGET-FAMILY; PRIVILEGED SUBSTRUCTURES; MOLECULAR COMPLEXITY; FUNCTIONAL COVERAGE; MEDICINAL CHEMISTRY;
D O I
10.1039/c2md20242e
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
The ability of small molecules to interact with multiple proteins is commonly referred to as polypharmacology. The now widely accepted polypharmacology of drugs is of particular interest for human health as it has implications beyond therapeutic efficacy, from anticipating adverse drug reactions to identifying potential repurposing opportunities. There have been a number of studies relating the extent of drug polypharmacology to the physicochemical properties and fragment composition of the drug itself, but also to the protein family and distant binding site similarities of the drug's primary target. Taken together, all these observations lead to speculate that the origins of drug polypharmacology may lie at the heart of protein evolution and that polypharmacology may just be a reminiscent signature of some of the mechanisms of adaptation that primitive biological systems developed to increase the chances of survival in a highly variable early chemical environment.
引用
收藏
页码:80 / 87
页数:8
相关论文
共 136 条
[1]
The 'evolvability' of promiscuous protein functions [J].
Aharoni, A ;
Gaidukov, L ;
Khersonsky, O ;
Gould, SM ;
Roodveldt, C ;
Tawfik, DS .
NATURE GENETICS, 2005, 37 (01) :73-76
[2]
Kinase-targeted libraries: The design and synthesis of novel, potent, and selective kinase inhibitors [J].
Akritopoulou-Zanze, Irini ;
Hajduk, Philip J. .
DRUG DISCOVERY TODAY, 2009, 14 (5-6) :291-297
[3]
Strategies to Discover Unexpected Targets for Drugs Active at G Protein-Coupled Receptors [J].
Allen, John A. ;
Roth, Bryan L. .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 51, 2011, 2011, 51 :117-144
[4]
[Anonymous], 1872, The origin of species
[5]
[Anonymous], 2013, Guidelines for ATC Classification and DDD assignment 2014, V17th
[6]
Drug repositioning: Identifying and developing new uses for existing drugs [J].
Ashburn, TT ;
Thor, KB .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) :673-683
[7]
Azzaoui K, 2007, CHEMMEDCHEM, V2, P874, DOI 10.1002/cmdc.200700036
[8]
Computational analysis of ligand relationships within target families [J].
Bajorath, Juergen .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2008, 12 (03) :352-358
[9]
Ban Thomas A, 2006, Dialogues Clin Neurosci, V8, P335
[10]
Ligand specificity, privileged substructures and protein druggability from fragment-based screening [J].
Barelier, Sarah ;
Krimm, Isabelle .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2011, 15 (04) :469-474